Your session is about to expire
← Back to Search
An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System
N/A
Waitlist Available
Led By Jashvant Poeran, MD, PhD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days post-discharge regarding hospitalization during which a high-risk drug was prescribed
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if changing the default dose settings in electronic prescribing can help doctors choose safer doses for elderly patients. It focuses on hospitalized patients aged 65 and older, aiming to reduce inappropriate prescribing of high-risk drugs.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days post-discharge regarding hospitalization during which a high-risk drug was prescribed
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days post-discharge regarding hospitalization during which a high-risk drug was prescribed
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Prescription rate of modified default dose for eight high-risk drugs
Secondary study objectives
Cost of hospital stay
Drug-specific prescription rate
Length of hospital stay
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
The first option a prescriber sees when prescribing any of eight high-risk drugs for elderly hospitalized patients will be modified; the first frequency option a prescriber sees will be modified as well. Providers retain the ability to prescribe any dose or frequency.
Group II: ControlActive Control1 Intervention
No change in default dose or frequency selected for the eight targeted drugs
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EHR-based "nudge" interventions
2022
N/A
~8640
Find a Location
Who is running the clinical trial?
NYC Health + HospitalsUNKNOWN
3 Previous Clinical Trials
55,341 Total Patients Enrolled
Icahn School of Medicine at Mount SinaiLead Sponsor
909 Previous Clinical Trials
533,520 Total Patients Enrolled
Jashvant Poeran, MD, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai